Correlates of Urea Kinetic Modeling during Hemodialysis in Patients with Acute Renal Failure

Abstract

The current guidelines on dialysis adequacy in acute renal failure (ARF) are loosely defined and have been extrapolated from patients with end-stage renal disease. The objectives of this study were (1) to compare three methods of urea kinetic modeling measurement in patients with ARF receiving intermittent hemodialysis, (2) to compare prescribed to delivered dose of dialysis, and (3) to explore the factors that are associated with dialysis delivery. ‘Single-pool’ urea kinetic modeling was assessed by the Ureakin^® software and the second-generation equation which uses a logarithmic estimate of spKt/V. ‘Equilibrated’ Kt/V (eKt/V) was calculated using the rate adjustment equation. The prescribed dose was derived using the manufacturer’s specifications of the dialyzer clearance, prescribed time, actual delivered blood and dialysate flow, and estimates of volume of urea distribution. A total of 78 consecutive spKt/V measurements were obtained in 24 patients. The mean urea reduction ratio was 51 ± 1%. The delivered spKt/V was significantly lower than that prescribed (0.87 ± 0.03 or 0.83 ± 0.03 vs. 1.28 ± 0.05; p = 0.0001). The equilibrated Kt/V was markedly lower than the delivered spKt/V (0.73 ± 0.03 vs. 0.83 ± 0.03; p = 0.0001). Univariate analyses demonstrated that female gender, low body mass index, low predialysis weight, use of cellulose acetate dialyzers, and increased prescribed time were associated with increased odds of prescribed spKt/V ≧1.2. Similarly, old age, increased delivered time, and high cytokine production were associated with increased odds of delivered spKt/V ≧1.2. In summary, while the impact of delivered intermittent hemodialysis on the survival of patients with ARF remains to be determined, these results indicate that dialysis delivery is suboptimal in ARF, and empiric dosing should strongly consider factors related to lean body mass, including age and gender.

Journal

Journal ID (publisher-id): BPU

Journal ID (nlm-ta): Blood Purif

Journal ID (doi): 10.1159/issn.0253-5068

Title: Blood Purification

Publisher: S. Karger AG

ISSN (Print): 0253-5068

ISSN (Electronic): 1421-9735

Publication date Subscription-year: 2002

Publication date (Print): 2002

Publication date (Electronic): 30 January 2002

Volume: 20

Issue: 2

Pages: 154-160

Affiliations

Divisions of ^aNephrology and ^bClinical Care Research, Department of Medicine, New England Medical Center, Boston, Mass., USA

Article

Publisher ID: 47002 Other ID: Blood Purif 2002;20:154–160

DOI: 10.1159/000047002

PubMed ID: 11818678

Copyright statement: © 2002 S. Karger AG, Basel

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Page count

Figures: 1, Tables: 2, References: 33, Pages: 7

Product

Self URI (application/pdf): https://www.karger.com/Article/Pdf/47002

Self URI (text/html): https://www.karger.com/Article/FullText/47002

Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology

Categories

Subject: Original Paper